Diagnosis and Surgical Treatment of Human Brucellar Spondylodiscitis

Podsumowanie

We describe a clinical algorithm, based on decades of front-line experience of diagnosis and surgical treatment of human Brucellar spondylodiscitis in the largest medical center of the China's Xinjiang Pastoral Area.

Streszczenie

Brucellar spondylodiscitis (BS) is the most prevalent and significant osteoarticular presentation of human Brucellosis, which is commonly manifested in pastoral communities. It is difficult to differentially diagnose and usually leads to irreversible neurologic deficits and spinal deformities. The initial diagnosis of BS is based on clinical findings and radiographic assessments, and the confirmed diagnosis should be established by the isolation of Brucella species from the blood and/or the standard tube agglutination test. Differential diagnosis of multifocal BS from either degenerative disc diseases or tuberculosis is especially highlighted. The surgical approach, either endoscopic or open, is demonstrated in detail, accompanied by radiographic evidence of structural compression or severe instability. Further, the crucial surgical steps, including single-stage transforaminal decompression, debridement, interbody fusion, and internal fixation, are explained. Moreover, perioperative care and postoperative rehabilitation are also addressed. Taken together, this clinical algorithm presents a practical guide that has yielded substantially satisfactory outcomes in the past decades, which can also be introduced for large-scale application to manage human BS, especially in endemic regions.

Wprowadzenie

With more than half a million new cases annually, human Brucellosis has become a public health concern and remains an enormous burden worldwide^1,2,3,4. BS, as the most common and severe osteoarticular manifestation of human Brucellosis, involves multiple structures including vertebral bodies, intervertebral disc, and paraspinal structures^5,6. It occurs frequently in the lumbosacral zone and needs to be differentiated from other infectious diseases because of its nonspecific clinical characteristics^7,8. Despite the significant advances in research over the past decades, accurate and timely diagnosis of BS is still a challenge for clinicians due to its late-onset radiological findings, slow growth rate in blood cultures, and the complexity of its serodiagnosis⁹. Therefore, human BS remains clinically underdiagnosed and underreported. Although the past decades have seen increasingly rapid advances in the introduction and popularization of several therapeutic guidelines, there is still no consensus for an optimal management modality¹⁰. Frequent relapses, treatment failure, and sequelae are reported constantly¹¹.

Of note, BS can be severely debilitating and disabling even if it is rarely fatal. If it is not treated appropriately, possible serious sequelae might be induced including persistent back pain, neurological deficiency, and even kyphotic deformity^12,13. Antibiotic therapy is the core in the treatment of BS and yields generally promising outcomes⁹. However, certain patients may require surgical treatment if neurological dysfunction, spinal instability, abscess formation, intractable pain, or a previous unsatisfactory response to conservative treatments are observed. Surgical intervention remains controversial. Different surgical procedures for debridement and fusion have been described for infectious diseases of the lumbar spine including anterior-only, posterior-only, and combined approaches^14,15,16. Here, diagnostic guidelines have been presented for human BS and for the single-stage surgical treatment with transforaminal decompression, debridement, interbody fusion, and internal fixation via a posterior-only approach. A detailed protocol of this method is given below.

Protokół

The study was approved by the ethical committee of the First Affiliated Hospital of Xinjiang Medical University, China¹⁷.

1. Informed Consent

1. Obtain the patient's informed consent after explaining the details of the surgical procedure, postoperative prognosis, and possible complications (infection, epidural hematoma, spinal cord injury, failure of internal fixation, and cerebrospinal fluid leakage).
2. Explain the other risks generally associated with using an implant (e.g., internal fixation system) such as allergic or immune system responses to the implanted materials.
3. Rule out any contraindications of the patients.

2. Patient selection

1. Diagnosis of BS
   1. Base the initial diagnosis of BS on the clinical manifestations and radiographic assessments⁸.
      1. Look for clinical manifestations and symptoms such as back pain, undulant fever, malaise, profuse night sweating, weight loss, polyarthralgia, and generalized myalgias^8,18.
      2. In plain radiographs, look for osteophytes, sclerosis, osteoporosis of the vertebral body, and narrowing of the intervertebral disc space, with posterior elements being mostly preserved.
         NOTE: Central necrosis is mostly not present, and the vertebral body is mostly morphologically intact (Figure 1)¹⁸.
      3. In computed tomography (CT), look for small bone destruction lesions at vertebral edges that occur in multiple areas, and for hyperplastic and sclerotic lesions that are more prominent and often admixed (Figure 1)¹⁸.
         ​NOTE: CT features are divided into those of vertebral osteolysis and vertebral hyperplastic sclerosis stages¹⁹.
      4. As magnetic resonance imaging (MRI) is the best imaging tool for BS diagnosis (Figure 1)^20,21,22, look for characteristic MRI findings that can be classified into five subsets: discitis, spondylitis, paraspinal/psoas abscess, appendicitis, and compound (Table 1).
   2. Confirm the diagnosis according to the presence of the following three criteria²³:
      1. Ensure that the clinical picture is compatible with that of BS.
      2. Confirm the absence of any etiology other than Brucellosis that can explain spinal involvement.
      3. Confirm that the results of the standard tube agglutination test reveal a titer of antibodies to Brucella of ≥ 1/160²⁴.
2. Indications for surgery²³
   1. Look for persistent pain due to spinal instability, which is caused by severe disc or/and vertebral destruction.
   2. Confirm severe or progressive neurologic dysfunction that can be attributed to nerve root compression by inflammatory granuloma or epidural abscesses.
   3. Confirm that there is no response to oral antibiotic therapy (e.g., doxycycline, rifampicin, streptomycin).

3. Preoperative procedure

1. Administer a chemotherapy regimen (oral doxycycline 200 mg/day plus oral rifampicin 600-900 mg/day)²⁵ to all patients.
2. Offer surgical interventions to patients who have surgical indications after two weeks of antibiotic treatment.

4. Operative procedures for single-stage transforaminal decompression, debridement, interbody fusion, and internal fixation via posterior-only approach

1. Place the patient on a four-poster frame in the prone position after administration of general anesthesia with endotracheal intubation.
2. Disinfect the surgical area with 1% iodophor, and then cover with standard surgical towels (see Table of Materials).
3. Make a midline longitudinal incision over the spinous process of the infected vertebra.
4. Expose the posterior spinal structures including lamina, facet joints, and transverse processes.
5. Place the pedicle screws (diameter: 5-7 mm, length: 20-65 mm) into both sides of the affected vertebra with the assistance of C-arm fluoroscopy^26,27,28 (see Table of Materials).
   NOTE: To achieve adequate debridement, place the pedicle screws closest to the superior or inferior endplate and away from the infection lesions. Fix the screws to a temporary rod (diameter: 5.5 mm) on the less involved side (see Table of Materials).
6. Perform the facetectomy at the involved level on the side where neurologic and radiological manifestations are more severe²⁹.
7. Debride the epidural abscess, granulation tissues, infected disc with curettes, and scrape the vertebral endplates. Meanwhile, protect the nerve root with a nerve retractor (see Table of Materials).
   NOTE: Perform a blunt dissention to adequately drain the psoas abscess from the posterolateral as thoroughly as possible. Analyze the tissues and abscess histopathologically^30,31. Noncaseating granulomatous inflammation with predominant lymphocyte and monocytes infiltration is the typical histopathologic finding of BS³². If the result of decompression and debridement is not satisfactory after a unilateral facetectomy, perform the same procedure on the opposite side.
8. After adequately removing the lesions and decompressing the neural elements, use 1000-2000 mL of 0.9% sodium chloride solution for surgical area irrigation to clear the residual Brucellar lesion (see Table of Materials).
9. Saturate an absorbable gelatin sponge (60 mm x 20 mm x 5 mm) with 0.75-1.5 g of streptomycin, and use it for both hemostasis and local antibiotic treatment within the surgical area (see Table of Materials).
10. Implant the locally harvested autogenous bone into the defected space for interbody fusion with a bone graft funnel and bone pusher (see Table of Materials).
11. Fix pedicle screws (diameter: 5-7 mm, length: 20-65 mm) on both sides to the pre-contoured rods (diameter: 5.5 mm) under a slight compression^33,34 (see Table of Materials).
12. Drain and close the lesion³⁵ (see Table of Materials).

5. Postoperative management

1. Administer intravenous antibiotic (cefuroxime sodium, 1.5 g, q12h) for 1-3 days postoperatively.
2. Remove the drainage tube when the drainage volume is less than 30 mL per day.
3. Administer the aforementioned antibiotic therapies with doxycycline (200 mg/day) and rifampicin (600-900 mg/day) for at least 3 months (range 3-12 months) after surgery.
4. Ensure the patient remains in bed for 3-5 days postoperatively, and allow for mobilization by providing effective support with a lumbosacral brace.
5. Perform plain radiography before the patient's discharge to evaluate the location of the graft and instrumentation.
6. Ensure at least 2-3 months of brace protection.

6. Follow-up evaluation

1. Follow up with the patients at 1, 3, and 6 months postoperatively and then annually.
2. Monitor the infection by measuring erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
3. Evaluate interbody fusion by radiography at the last follow-up.
   NOTE: Assess graft fusion with the radiologic criteria of Bridwell³⁶. Perform CT scans if there is any uncertainty regarding plain radiographs.
4. Utilize the visual analogue scale (VAS) to assess back pain.
5. Evaluate pain-related dysfunction with the Oswestry Disability Index (ODI).
6. Use the Japanese Orthopedic Association (JOA) scale to evaluate the functional outcomes.

Wyniki

This paper describes a prospective, non-randomized, controlled study of 32 consecutive BS patients who were treated by a single-stage transforaminal decompression, debridement, interbody fusion, and internal fixation via a posterior-only approach in the Department of Spine Surgery, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China. Figure 1 shows a typical case in this study.

T...

Dyskusje

The present guideline of diagnosis and surgical treatment of human BS with a detailed protocol and satisfactory clinical evidence from representative cohorts shows clinical efficacy and is proposed for large-scale application to manage human BS, especially in endemic regions. The first critical step in the treatment of BS is to make the correct diagnosis. The diagnosis of BS needs to be differentiated from spinal tuberculosis compared to which BS is relatively less bone-destructive and usually responds effectively to ant...

Materiały

Name	Company	Catalog Number	Comments
Absorbable gelatin sponge	Chuhe Medical Devices Co., Ltd.	AWZ-035-XSMJHM-AD.	60 mm x 20 mm x 5 mm
Box curette	Rudischhauser GmbH	R16-BD2310-ST	Width: 7.5 mm; height: 5.9 mm; shaft: 6.0 mm (diameter); working length: 223 mm
Bone graft funnel	Rudischhauser GmbH	R19-K00000-FU	Working length: 246.5 mm; End diameter: 42 mm; shaft: 6.4 mm (diameter)
Bone pusher	Rudischhauser GmbH	R19-EK4110-00	Working length: 220 mm; shaft: 6.0 mm (diameter)
Bone rongeur	Vet Direct & VETisco	EC-RG-BO-180	Length: 180 mm
Iodophor (1%)	Beijing SanYao Science & Technology Development Co.	14975I	Volume: 500 mL
Nerve retractor	Rudischhauser GmbH	R16-HD1710-00	Width: 10 mm; length: 145 mm; shaft: 5.0 mm (diameter)
Osteotome 1	Rudischhauser GmbH	R16-CD2310-08	Width: 8 mm; height: 3 mm; shaft: 6.0 mm (diameter); working length: 223 mm
Osteotome 2	Rudischhauser GmbH	R16-CD2310-10	Width: 10 mm; height: 3 mm; shaft: 6.0 mm (diameter); working length: 223 mm
Pedicle screw	DePuy Synthes Companies	199723540	Length: 40 mm; diameter: 5.0 mm
	DePuy Synthes Companies	199723545	Length: 45 mm; diameter: 5.0 mm
	DePuy Synthes Companies	199723550	Length: 50 mm; diameter: 5.0 mm
	DePuy Synthes Companies	199723640	Length: 40 mm; diameter: 6.0 mm
	DePuy Synthes Companies	199723645	Length: 45 mm; diameter: 6.0 mm
	DePuy Synthes Companies	199723650	Length: 50 mm; diameter: 6.0 mm
	DePuy Synthes Companies	199723740	Length: 40 mm; diameter: 7.0 mm
	DePuy Synthes Companies	199723745	Length: 45 mm; diameter: 7.0 mm
	DePuy Synthes Companies	199723750	Length: 50 mm; diameter: 7.0 mm
Securo Drain	Dispomedica GmbH	1.33578	Size: 7 mm; Length of perforation: 15 cm; Total length: 80 cm; Reservior size: 150 ml
Sterile 0.9% Sodium Chloride Solution	Beijing SanYao Science & Technology Development Co.	15935S	Volume: 500 mL
Straight rod	DePuy Synthes Companies	1797-62-480	Length: 480 mm; diameter: 5.5 mm
Streptomycin sulfate, Powder	Beijing SanYao Science & Technology Development Co.	P06-11025P	Size: 1 g